Search

Boehringer Ingelheim annouces 2020 BVDzero Case Awards

Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.

Major investment for respiratory diseases completed

105 million euros invested into expansion of production facilities in Ingelheim and Dortmund

Boehringer Ingelheim leader in hatchery vaccination

Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.

Veterinarians: caught between excellence and exhaustion

Many children dream of becoming a veterinarian. What happens when that dream comes true?

Careers beyond borders

Tomorrow's leaders

We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.

License deal with A*STAR to develop cancer antibodies

Supply Chain Scholarship for Cowtribe

A supply chain course we sponsored boosted the career of Latifa Saaka

Lady, a guide dog in the office

A great partnership between a Boehringer Ingelheim employee and her guide dog at work. Their relationship goes beyond the human-animal bond.

AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance

AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance

EHS management approach

We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness

IL-11 inhibitor antibody clinical development launched

Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment

Innovation and drone delivery

Addressing healthcare disparities through collaborative innovation and drone delivery

Partnership with IBM to accelerate new antibody therapies

Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development

Survodutide Phase III study weight loss

Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity

Boehringer and ZEISS partnership eye diseases

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Keep water clean

Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.

Boehringer Ingelheim Ruminant Well-Being Awards 2020

The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.

Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program

EMA authorization for Reprocyc ParvoFLEX

Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine

Winners of the 2019 European PRRS Research Award

Winners of the 2019 European PRRS Research Award announced.

FRONTLINE becomes Brand of the Year 2019-2020

FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards

Launch of Frontline flagship store on Tmall

Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.

antibiotic resistance one health veterinary medicine

Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers